Obiltoxaximab

(Anthim®)

Obiltoxaximab

Latest News

loading GIF

Drug updated on 4/26/2024

Dosage FormInjection (intravenous; 600 mg/6 mL)
Drug ClassMonoclonal antibody against B. anthracis
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in adult and pediatric patients for treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs and, for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Obiltoxaximab (Anthim) is indicated for the treatment of inhalational anthrax in adults and pediatric patients, used in combination with appropriate antibacterial drugs. It is also used for prophylaxis when alternative therapies are not available or suitable.
  • A single systematic review/meta-analysis was reviewed to gather information about this drug.
  • The efficacy of obiltoxaximab has been demonstrated through studies involving New Zealand White rabbits and cynomolgus macaques, showing higher survival rates post-exposure to inhalational anthrax compared to control groups.
  • Safety evaluations conducted on healthy human volunteers indicate that obiltoxaximab is well-tolerated with a relatively low incidence of adverse events, suggesting a favorable safety profile, especially considering the severity of inhalational anthrax and the limited treatment options available.
  • While no direct comparison between obiltoxaximab and other antitoxins or antibacterial drugs was provided in the study, it acknowledges its value as an addition to existing treatments, particularly where alternatives are unsuitable or unavailable.
  • Although specific data regarding different age groups were not detailed within the study, both adult and pediatric patients can be treated with obiltoxaximab, indicating its wide-ranging suitability across various ages, which is crucial during public health responses to incidents related to exposure to Anthrax.

Product Monograph / Prescribing Information

Document TitleYearSource
Anthim (obiltoxaximab) Prescribing Information.2019Therapeutics, Inc., Parsippany, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Obiltoxaximab: Adding to the treatment arsenal for bacillus anthracis infection2017The Annals of Pharmacotherapy

Clinical Practice Guidelines